Expert Perspectives on Biosimilar Agents

Download All
This in-depth educational program, which features a video module, downloadable slideset with slidenotes, and a series of ClinicalThought commentaries, illuminates expert perspectives on biosimilars with a specific emphasis on their application in the oncology, rheumatology, and gastroenterology specialties.
Russell D. Cohen, MD, FACG, AGAF
Andrew M. Evens, DO, MSc, FACP
Jonathan Kay, MD
Alan C. Moss, MD

Expert Perspectives on Biosimilar Agents

In this video module, a multidisciplinary panel of expert faculty discuss the use of biosimilars across oncology, rheumatology, dermatology, and gastroenterology specialties.

This program is divided into four segments. After clicking the Launch buttons below, the player will open in a new window. If it doesn’t appear, please disable your pop-up blocker and try again.

Andrew M. Evens, DO, MSc, FACP Jonathan Kay, MD Alan C. Moss, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: November 16, 2017 Expired: No longer available for credit

In these downloadable slides, a multidisciplinary panel of expert faculty discuss the use of biosimilars across oncology, rheumatology, dermatology, and gastroenterology specialties.

Released: November 16, 2017

ClinicalThought

As biosimilars penetrate the GI treatment space, here’s my take on what gastroenterologists need to know.

Russell D. Cohen, MD, FACG, AGAF Released: December 6, 2017

Despite demonstration of comparable efficacy and safety between biosimilars and their originators, some patients avoid this treatment switch. Here’s my take on steps to assuage unfounded patient fears.

Jonathan Kay, MD Released: February 13, 2018
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue